Curaleaf Launches New High-CBD Flower Range for UK Patients

Curaleaf UK, one of the largest medical cannabis operators in the country, has launched a new range of high-CBD flower products specifically developed for UK patients who benefit from cannabinoid therapy but prefer minimal psychoactive effects. The range addresses a growing segment of the patient population seeking daytime-compatible treatments.

The New Product Range

The range comprises three distinct cultivars, each standardised for high CBD content and very low THC levels. The products are cultivated under pharmaceutical-grade conditions and are available through clinic networks and partner pharmacies. All three cultivars are approved for use with medical vaporiser devices.

• Cultivar A: High CBD, less than 0.3% THC, suitable for daytime use
• Cultivar B: Balanced minor cannabinoid profile with elevated CBD and CBG
• Cultivar C: CBD-dominant with terpene profile optimised for calming effects

Who Is This Range For

The new products are intended for patients whose conditions respond to CBD-dominant formulations, including those being treated for anxiety, inflammation-related pain, and certain neurological conditions. They are also appropriate for patients who have previously experienced unwanted psychoactive effects from THC-containing products and wish to explore a gentler alternative.

You can explore all currently available CBD-dominant flower products in our strain directory, or visit our clinic finder to locate a specialist near you. Our prescription guide provides a clear overview of the steps involved for new patients. Patients with anxiety should also review our anxiety treatment guide for condition-specific information.